Amarin Corporation PLC是一家制药公司。该公司专注于改善心血管(CV)、健康和降低CV风险的疗法的商业化和开发。该公司通过VASCEPA的开发和商业化运营。其主导产品Vasicpa(icosapent ethyl)胶囊被用作饮食的辅助药物,以降低患有严重高甘油三酯血症的成年患者的甘油三酯水平。Vascepa的这一适应症被称为MARINE适应症,主要基于Vascepa在该获批患者群体中的MARINE研究结果。该公司主要将Vascepa销售给批发商以及选定的区域批发商和专业药房供应商,或统称为其分销商,后者又将Vascepa转售给零售药店,再转售给患者和医疗保健提供者。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Odysseas D. Kostas | Independent Non-Executive Chairperson of the Board | 2023 | 51 |
| Aaron D. Berg | CEO, President & Director | 2024 | 63 |
| John Climax | Chairman of Scientific Advisory Board | 2006 | 73 |
| Louis E. Sterling | Independent Non-Executive Director | 2023 | 47 |
| Diane E. Sullivan | Independent Non-Executive Director | 2023 | 63 |
| Jan D. Wallace | Member of Scientific Advisory Board | 2006 | 85 |
| Mark W. Pierce | Member of the Scientific Advisory Board | 2006 | - |
| Reid Patterson | Member of the Scientific Advisory Board | 2006 | - |
| Patrice Eadon Bonfiglio | Independent Non-Executive Director | 2023 | 43 |
| Keith L. Horn | Independent Non-Executive Director | 2023 | 67 |
| Paul Cohen | Independent Non-Executive Director | 2023 | 51 |
| Oliver O'Connor | Independent Non-Executive Director | 2023 | 64 |
| Michael Patrick Torok | Non-Employee Director | 2025 | 47 |